Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics, Degussa Partner on Arthritis Nutraceuticals

NEW YORK, April 7 - Galapagos Genomics, a functional genomics company based in Belgium, said today that it is collaborating with Degussa BioActives to identify nutraceuticals with beneficial effects in the field of arthritis.

 

Galapagos will design human cellular assays based on its functional genomics platform, and will screen libraries of natural compounds to identify leads. Degussa has exclusive rights to commercialize any nutraceuticals that result from the collaboration, while Galapagos is eligible for milestone payments and royalties on the commercialization of these products.

 

Onno van de Stolpe, CEO of Galapagos, said the partnership is the company's first foray into the nutraceutical field, and "has the potential to become an important income generator for Galapagos."

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.